ASK120067 is currently in a phase I/II clinical trial (NCT03502850) comprising patients with advanced EGFR T790M-positive NSCLC who had disease progression following treatment with EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.